Please login to the form below

Not currently logged in
Email:
Password:

Retrophin

This page shows the latest Retrophin news and features for those working in and with pharma, biotech and healthcare.

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets

What a difference a year makes. Under pressure in 2015, US firm Retrophin now has a positive trial in hand for a rare disease drug that some analysts say could approach ... Last year, Retrophin was indirectly caught up in the scandal surrounding its

Latest news

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    More recently Retrophin sold its PRV to Sanofi for $245m, so it looks as though values are definitely on the rise!

  • Pharma deals in May 2015 Pharma deals in May 2015

    Sanofi purchased the paediatric PRV from Retrophin for the total consideration of $245m ($150m on closure with two subsequent payments in 2016 and 2017 of $47.7m). ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    Licence termination. DiaPep277 for type 1 diabetes patients. 72. Manchester Pharmaceuticals / Retrophin.

  • Pharma deals during February 2014 Pharma deals during February 2014

    Recently public, Retrophin has acquired Manchester Pharmaceuticals, a speciality pharmaceutical company that focuses on treatments for rare diseases. ... Retrophin is paying a total of $62.5m, including an upfront of $29.5m, plus royalties based on

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Amryt Pharma appoints new regulatory affairs head Amryt Pharma appoints new regulatory affairs head

    Derval O’Carroll joins the rare disease-focused biopharma from Retrophin. Rare and orphan disease-focused biopharmaceutical group Amryt Pharma has appointed a new head of regulatory affairs in the form ... Prior to joining Amryt, she served as senior

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics